Literature DB >> 12788824

Chronic cardiotoxicity of anticancer anthracyclines in the rat: role of secondary metabolites and reduced toxicity by a novel anthracycline with impaired metabolite formation and reactivity.

Giuseppe Sacco1, Rossella Giampietro, Emanuela Salvatorelli, Pierantonio Menna, Nicoletta Bertani, Gallia Graiani, Fabio Animati, Cristina Goso, Carlo A Maggi, Stefano Manzini, Giorgio Minotti.   

Abstract

(1) The anticancer anthracycline doxorubicin (DOX) causes cardiomyopathy upon chronic administration. There is controversy about whether DOX acts directly or after conversion to its secondary alcohol metabolite DOXol. Here, the role of secondary alcohol metabolites was evaluated by treating rats with cumulative doses of DOX or analogues--like epirubicin (EPI) and the novel disaccharide anthracycline MEN 10755--which were previously shown to form less alcohol metabolites than DOX when assessed in vitro. (2) DOX induced electrocardiographic and haemodynamic alterations, like elongation of QalphaT or SalphaT intervals and suppression of isoprenaline-induced dP/dt increases, which developed in a time-dependent manner and were accompanied by cardiomegaly, histologic lesions and mortality. EPI caused less progressive or severe effects, whereas MEN 10755 caused essentially no effect. (3) DOX and EPI exhibited comparable levels of cardiac uptake, but EPI formed approximately 60% lower amounts of its alcohol metabolite EPIol at 4 and 13 weeks after treatment suspension (P<0.001 vs DOX). MEN 10755 exhibited the lowest levels of cardiac uptake; hence, it converted to its alcohol metabolite MEN 10755ol approximately 40% less efficiently than did EPI to EPIol at either 4 or 13 weeks. Cardiotoxicity did not correlate with myocardial levels of DOX or EPI or MEN 10755, but correlated with those of DOXol or EPIol or MEN 10755ol (P=0.008, 0.029 and 0.017, respectively). (4) DOX and EPI inactivated cytoplasmic aconitase, an enzyme containing an Fe-S cluster liable to disassembly induced by anthracycline secondary alcohol metabolites. DOX caused greater inactivation of aconitase than EPI, a finding consistent with the higher formation of DOXol vs EPIol. MEN 10755 did not inactivate aconitase, which was because of both reduced formation and impaired reactivity of MEN 10755ol toward the Fe-S cluster. Aconitase inactivation correlated (P<0.01) with the different levels of cardiotoxicity induced by DOX or EPI or MEN 10755. (5) These results show that (i) secondary alcohol metabolites are important determinants of anthracycline-induced cardiotoxicity, and (ii) MEN 10755 is less cardiotoxic than DOX or EPI, a behaviour attributable to impaired formation and reactivity of its alcohol metabolite.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12788824      PMCID: PMC1573869          DOI: 10.1038/sj.bjp.0705270

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  28 in total

1.  Doxorubicin disaccharide analogue: apoptosis-related improvement of efficacy in vivo.

Authors:  F Arcamone; F Animati; M Berettoni; M Bigioni; G Capranico; A M Casazza; C Caserini; A Cipollone; M De Cesare; M Franciotti; P Lombardi; A Madami; S Manzini; E Monteagudo; D Polizzi; G Pratesi; S C Righetti; C Salvatore; R Supino; F Zunino
Journal:  J Natl Cancer Inst       Date:  1997-08-20       Impact factor: 13.506

Review 2.  Doxorubicin cardiotoxicity: analysis of prevailing hypotheses.

Authors:  R D Olson; P S Mushlin
Journal:  FASEB J       Date:  1990-10       Impact factor: 5.191

3.  Superoxide anion production by adriamycinol from cardiac sarcosomes and by mitochondrial NADH dehydrogenase.

Authors:  P G Gervasi; M R Agrillo; L Citti; R Danesi; M Del Tacca
Journal:  Anticancer Res       Date:  1986 Sep-Oct       Impact factor: 2.480

4.  Anthracyclines - a review of general and special toxicity studies.

Authors:  G Mazue; M Iatropoulos; A Imondi; S Castellino; M Brughera; A Podesta; P Dellatorre; D Moneta
Journal:  Int J Oncol       Date:  1995-10       Impact factor: 5.650

5.  Human carbonyl reductase overexpression in the heart advances the development of doxorubicin-induced cardiotoxicity in transgenic mice.

Authors:  G L Forrest; B Gonzalez; W Tseng; X Li; J Mann
Journal:  Cancer Res       Date:  2000-09-15       Impact factor: 12.701

6.  Secondary alcohol metabolites mediate iron delocalization in cytosolic fractions of myocardial biopsies exposed to anticancer anthracyclines. Novel linkage between anthracycline metabolism and iron-induced cardiotoxicity.

Authors:  G Minotti; A F Cavaliere; A Mordente; M Rossi; R Schiavello; R Zamparelli; G Possati
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

7.  Protection against daunorubicin cytotoxicity by expression of a cloned human carbonyl reductase cDNA in K562 leukemia cells.

Authors:  B Gonzalez; S Akman; J Doroshow; H Rivera; W D Kaplan; G L Forrest
Journal:  Cancer Res       Date:  1995-10-15       Impact factor: 12.701

Review 8.  Epirubicin. Clinical pharmacology and dose-effect relationship.

Authors:  J Robert
Journal:  Drugs       Date:  1993       Impact factor: 9.546

9.  Activation of nuclear factor-kappaB during doxorubicin-induced apoptosis in endothelial cells and myocytes is pro-apoptotic: the role of hydrogen peroxide.

Authors:  Suwei Wang; Srigiridhar Kotamraju; Eugene Konorev; Shasi Kalivendi; Joy Joseph; Balaraman Kalyanaraman
Journal:  Biochem J       Date:  2002-11-01       Impact factor: 3.857

10.  Quantitative experimental evaluation of adriamycin cardiotoxicity in the mouse.

Authors:  C Bertazzoli; O Bellini; U Magrini; M G Tosana
Journal:  Cancer Treat Rep       Date:  1979 Nov-Dec
View more
  9 in total

1.  Pharmacogenomic screening for anthracycline-induced cardiotoxicity in childhood cancer.

Authors:  Folefac Aminkeng; Colin J D Ross; Shahrad R Rassekh; Michael J Rieder; Amit P Bhavsar; Shubhayan Sanatani; Daniel Bernstein; Michael R Hayden; Ursula Amstutz; Bruce C Carleton
Journal:  Br J Clin Pharmacol       Date:  2017-03-19       Impact factor: 4.335

2.  Tissue retention of doxorubicin and its effects on cardiac, smooth, and skeletal muscle function.

Authors:  Reid Hayward; David Hydock; Noah Gibson; Stephanie Greufe; Eric Bredahl; Traci Parry
Journal:  J Physiol Biochem       Date:  2012-08-14       Impact factor: 4.158

3.  Cell transplantation with a catheter-based approach: an efficient method for the treatment of heart failure with multiple lesions.

Authors:  M Chen; Z-C Fan; X-J Liu; J-L Deng; Q Yang; D-J Huang
Journal:  Cell Prolif       Date:  2006-12       Impact factor: 6.831

Review 4.  The related miRNAs involved in doxorubicin resistance or sensitivity of various cancers: an update.

Authors:  Zahra Torki; Davood Ghavi; Solmaz Hashemi; Yazdan Rahmati; Dara Rahmanpour; Majid Pornour; Mohammad Reza Alivand
Journal:  Cancer Chemother Pharmacol       Date:  2021-09-12       Impact factor: 3.333

5.  Quantitative subcellular study of transferrin receptor-targeted doxorubicin and its metabolite in human breast cancer cells.

Authors:  Jinhui Xu; Yuan Sheng; Feifei Xu; Ying Yu; Yun Chen
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2013-12-22       Impact factor: 2.441

6.  Adverse effects of doxorubicin and its metabolic product on cardiac RyR2 and SERCA2A.

Authors:  Amy D Hanna; Alex Lam; Steffi Tham; Angela F Dulhunty; Nicole A Beard
Journal:  Mol Pharmacol       Date:  2014-08-08       Impact factor: 4.436

7.  Schisandrin B prevents doxorubicin-induced chronic cardiotoxicity and enhances its anticancer activity in vivo.

Authors:  Yang Xu; Zhen Liu; Jie Sun; Qiangrong Pan; Feifei Sun; Zhiyu Yan; Xun Hu
Journal:  PLoS One       Date:  2011-12-02       Impact factor: 3.240

Review 8.  The role of iron in anthracycline cardiotoxicity.

Authors:  Elena Gammella; Federica Maccarinelli; Paolo Buratti; Stefania Recalcati; Gaetano Cairo
Journal:  Front Pharmacol       Date:  2014-02-26       Impact factor: 5.810

9.  Skeletal Muscle an Active Compartment in the Sequestering and Metabolism of Doxorubicin Chemotherapy.

Authors:  Sergio Fabris; David A MacLean
Journal:  PLoS One       Date:  2015-09-24       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.